Hospital
Major Hospital
Major Hospital was paid $14.18M by Medicaid between Jan 2018 and Dec 2024, across 158 billing codes. Its largest line is 99283, emergency room visit (moderate) — 12% of everything it billed.
33Billing provider infoMAJOR HOSPITAL
SHELBYVILLE, IN 46176
SHELBYVILLE, IN 46176
33aNPI1174555692assigned 07/07/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$14.18M
24GClaims422,418
24DCodes billed158
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Indiana
Rank by total paid#28 of 69
Median peer was paid$9.76M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 61,553 | $629K | |
| 2019 | 52,311 | $1.31M | |
| 2020 | 48,931 | $1.62M | |
| 2021 | 67,940 | $2.62M | |
| 2022 | 83,324 | $3.06M | |
| 2023 | 65,708 | $3.11M | |
| 2024incomplete | 42,651 | $1.83M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 15,578 | 13,127 | $1.73M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 12% | 19,373 | 15,614 | $1.72M |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 11% | 5,711 | 1,464 | $1.63M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.5% | 11,066 | 8,600 | $1.07M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 6.1% | 17,124 | 12,046 | $871K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 5.4% | 8,357 | 2,757 | $765K |
| 96361 | Intravenous infusion, hydration; each additional hour | 5.1% | 6,517 | 5,091 | $726K |
| 71045 | Radiologic examination, chest; single view | 4.8% | 5,128 | 4,078 | $676K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 3.0% | 8,714 | 4,705 | $432K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 3,274 | 2,659 | $262K |
| 99219 | 1.8% | 1,008 | 372 | $249K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.7% | 9,076 | 7,157 | $243K |
146 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 1,700 | $205K |
| 99232 | Hospital visit by a doctor, follow-up day | 1.3% | 6,082 | $186K |
| 36415 | Collection of venous blood by venipuncture | 1.2% | 89,714 | $169K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 45,669 | $168K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 4,848 | $160K |
| 80050 | General health panel | 1.0% | 1,191 | $149K |
| 80053 | Comprehensive metabolic panel | <1% | 27,180 | $141K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,108 | $130K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 861 | $128K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 800 | $126K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 849 | $126K |
| 36591 | <1% | 2,333 | $125K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,110 | $120K |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 1,221 | $108K |
| J0897 | Injection, denosumab, 1 mg | <1% | 368 | $102K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,280 | $100K |
| G0108 | Diabetes outpatient self-management training services, individual, per 30 minutes | <1% | 851 | $82K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,830 | $76K |
| 80061 | Lipid panel | <1% | 9,034 | $73K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,615 | $68K |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | <1% | 29 | $60K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 918 | $60K |
| 97161 | <1% | 466 | $53K | |
| 73630 | <1% | 1,572 | $49K | |
| 80306 | <1% | 3,493 | $44K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 38 | $42K |
| 52000 | <1% | 73 | $42K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 126 | $40K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 130 | $40K |
| 84484 | <1% | 6,389 | $38K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 45 | $38K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 255 | $38K |
| 87806 | <1% | 2,573 | $34K | |
| 81001 | <1% | 20,983 | $33K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,248 | $29K |
| 94010 | <1% | 726 | $29K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,045 | $28K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 414 | $26K |
| 86803 | <1% | 2,489 | $26K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,296 | $23K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 14 | $23K |
| 87899 | <1% | 1,876 | $20K | |
| 94060 | <1% | 398 | $19K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 483 | $19K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 234 | $19K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 587 | $18K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 587 | $18K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,791 | $17K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 507 | $17K |
| 84439 | <1% | 3,377 | $16K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 586 | $16K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 3,242 | $16K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 3,774 | $16K |
| 85027 | <1% | 4,381 | $15K | |
| J0248 | Injection, remdesivir, 1 mg | <1% | 60 | $12K |
| 64493 | <1% | 35 | $12K | |
| 97165 | <1% | 97 | $11K | |
| 76981 | <1% | 105 | $10K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 53 | $10K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 53 | $10K |
| 83690 | <1% | 3,087 | $9K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 173 | $9K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 691 | $8K |
| 97597 | <1% | 96 | $8K | |
| 94618 | <1% | 565 | $8K | |
| 73562 | <1% | 261 | $8K | |
| 86850 | <1% | 1,884 | $8K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 54 | $7K |
| 85610 | <1% | 5,277 | $7K | |
| 81025 | <1% | 1,328 | $7K | |
| 82607 | <1% | 831 | $6K | |
| 90792 | Psychiatric diagnostic evaluation with medical services | <1% | 49 | $6K |
| 83970 | <1% | 491 | $5K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 774 | $5K |
| 86592 | <1% | 1,622 | $5K | |
| G0378 | Hospital observation service, per hour | <1% | 61 | $5K |
| 87653 | <1% | 151 | $4K | |
| 86003 | <1% | 87 | $4K | |
| 82652 | <1% | 265 | $4K | |
| 87634 | <1% | 66 | $3K | |
| 82728 | <1% | 488 | $3K | |
| 76830 | Ultrasound, transvaginal | <1% | 13 | $3K |
| 87070 | <1% | 339 | $3K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 85 | $2K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 12 | $2K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 12 | $2K |
| 83550 | <1% | 533 | $2K | |
| 17250 | <1% | 36 | $2K | |
| 74018 | <1% | 13 | $2K | |
| 99217 | <1% | 188 | $2K | |
| 73610 | <1% | 44 | $2K | |
| 87510 | <1% | 110 | $2K | |
| 87480 | <1% | 110 | $2K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 84 | $2K |
| 82746 | <1% | 307 | $2K | |
| 83540 | <1% | 534 | $2K | |
| 82570 | <1% | 723 | $2K | |
| 93244 | <1% | 94 | $2K | |
| 99223 | Prolong inpt eval add15 m | <1% | 78 | $2K |
| 80177 | <1% | 118 | $1K | |
| 83880 | <1% | 77 | $1K | |
| 82043 | <1% | 578 | $1K | |
| 83735 | <1% | 599 | $1K | |
| 95012 | <1% | 457 | $984.29 | |
| 86762 | <1% | 91 | $954.52 | |
| 73110 | <1% | 40 | $923.87 | |
| 80069 | <1% | 258 | $918.21 | |
| 88112 | <1% | 18 | $871.10 | |
| 87340 | <1% | 157 | $862.12 | |
| 85651 | <1% | 362 | $853.93 | |
| 82785 | <1% | 97 | $838.01 | |
| 87660 | <1% | 45 | $833.59 | |
| 86376 | <1% | 161 | $832.84 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 105 | $832.10 |
| 86480 | <1% | 16 | $746.14 | |
| 82610 | <1% | 143 | $692.49 | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 17 | $637.58 |
| 64494 | <1% | 35 | $621.15 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 12 | $600.39 |
| 82950 | <1% | 159 | $598.59 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 15 | $592.93 |
| 94726 | <1% | 156 | $512.83 | |
| 86900 | <1% | 172 | $454.76 | |
| 93016 | <1% | 61 | $395.61 | |
| 84550 | <1% | 325 | $358.76 | |
| 84100 | <1% | 317 | $340.92 | |
| 86901 | <1% | 172 | $330.45 | |
| 82947 | <1% | 85 | $281.43 | |
| 84480 | <1% | 50 | $270.05 | |
| 93018 | <1% | 61 | $263.75 | |
| 80184 | <1% | 20 | $252.28 | |
| 73030 | <1% | 23 | $212.84 | |
| 84134 | <1% | 30 | $212.52 | |
| 93227 | <1% | 13 | $200.98 | |
| 84156 | <1% | 264 | $195.12 | |
| 86200 | <1% | 22 | $194.25 | |
| 92567 | <1% | 21 | $192.13 | |
| 80175 | <1% | 30 | $169.05 | |
| 99307 | <1% | 26 | $138.29 | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 12 | $115.09 |
| 82565 | <1% | 29 | $110.36 | |
| 86430 | <1% | 20 | $85.96 | |
| 80164 | <1% | 12 | $78.78 | |
| 84460 | <1% | 15 | $58.30 | |
| 94729 | <1% | 160 | $1.20 | |
| 99220 | 0% | 28 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCLAXTON, RYAN (CEO)
| Provider | Location | Paid |
|---|---|---|
| Major Multispecialty Associates | Shelbyville, IN | $4.79M |
| Major Hospital | Shelbyville, IN | $1.75M |
| Major Medical Group LLC | Shelbyville, IN | $670K |
| Priority Care, LLC | Shelbyville, IN | $68K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.